Clinical Chemistry • Complete Guide 2026

Liver Function Tests (LFTs): Complete Guide to Biomarkers, Liver Enzymes, Clinical Interpretation, and Laboratory Diagnosis 

 

A practical and comprehensive introduction to liver function testing, liver physiology, major hepatic biomarkers, and the laboratory patterns used to recognize hepatocellular injury, cholestasis, and impaired hepatic synthetic function.

Prepared by Dr. Omar Adwan | MedLab Academy

Part 1 Overview: This section explains what liver function tests are, why the term “LFTs” can be misleading, the essential physiological functions of the liver, and the major categories of laboratory biomarkers used in the assessment of liver disease.

Table of Contents – Part 1

1. Introduction to Liver Function Tests
2. Why the Term “LFTs” Can Be Misleading
3. Basic Liver Anatomy and Physiology
4. Major Physiological Functions of the Liver
5. Major Categories of Liver Biomarkers
6. Major Patterns of Liver Injury
7. General Clinical Approach to LFT Interpretation
8. Part 1 Summary

1. Introduction to Liver Function Tests

Liver function tests, commonly abbreviated as LFTs, are a group of laboratory tests used to evaluate hepatocellular injury, cholestasis, bilirubin metabolism, and the liver’s ability to synthesize important proteins.

These tests are frequently requested in patients with jaundice, abdominal pain, fatigue, nausea, suspected hepatitis, alcohol-related liver injury, metabolic disease, medication toxicity, or abnormal imaging findings. They are also commonly used to monitor patients with established liver disease.

Important concept: An abnormal liver test does not automatically confirm a specific liver disease. The results must be interpreted together with the patient’s symptoms, medical history, medications, imaging findings, and other laboratory investigations.

A typical liver panel may include:

• Alanine aminotransferase (ALT)
• Aspartate aminotransferase (AST)
• Alkaline phosphatase (ALP)
• Gamma-glutamyl transferase (GGT)
• Total bilirubin
• Direct bilirubin
• Albumin
• Total protein
• Prothrombin time (PT) or international normalized ratio (INR)

Some laboratories may also report additional markers such as globulin, albumin-to-globulin ratio, lactate dehydrogenase, ammonia, or serum bile acids depending on the clinical context.

2. Why the Term “Liver Function Tests” Can Be Misleading

The term liver function tests is widely used, but not every component of the panel directly measures liver function.

For example, ALT and AST mainly reflect cellular injury and enzyme leakage from damaged cells. They do not directly measure how effectively the liver performs its metabolic or synthetic functions.

In contrast, albumin and PT/INR provide more direct information about hepatic synthetic capacity, although these markers can also be affected by conditions outside the liver.

Markers of Hepatocellular Injury

ALT and AST rise when hepatocyte membranes are damaged and intracellular enzymes enter the bloodstream.

Markers of Cholestasis

ALP and GGT commonly increase when bile formation or bile flow is impaired.

Markers of Bilirubin Handling

9. Alanine Aminotransferase (ALT)

Alanine aminotransferase (ALT), previously called serum glutamic-pyruvic transaminase or SGPT, is an intracellular enzyme involved in amino acid metabolism. It catalyzes the reversible transfer of an amino group from alanine to alpha-ketoglutarate, producing pyruvate and glutamate.

ALT is found predominantly in the cytoplasm of hepatocytes. Although small amounts are present in other tissues, ALT is generally considered more liver-specific than AST.

Key interpretation: An increased ALT concentration usually indicates hepatocellular membrane injury and leakage of the enzyme into the circulation. However, ALT elevation alone does not identify the exact cause of liver injury.

Main Tissue Sources of ALT

• Liver hepatocytes
• Skeletal muscle in smaller concentrations
• Kidney tissue
• Cardiac muscle in relatively low concentrations

Common Causes of Increased ALT

Metabolic Liver Disease

Metabolic dysfunction-associated steatotic liver disease may cause persistent mild or moderate ALT elevation.

Viral Hepatitis

Acute or chronic viral hepatitis may increase ALT, sometimes to very high concentrations during acute hepatocellular injury.

Drug-Induced Liver Injury

Medications, herbal remedies, and toxic substances may produce hepatocellular, cholestatic, or mixed biochemical patterns.

Ischemic Liver Injury

Severe hepatic hypoperfusion may produce dramatic aminotransferase elevations, often reaching many times the upper reference limit.

Autoimmune Hepatitis

Autoimmune hepatocyte injury may produce substantial ALT and AST elevations together with characteristic immunological findings.

Muscle Injury

Although ALT is more liver-specific than AST, major muscle injury can occasionally contribute to increased ALT concentrations.

Magnitude of ALT Elevation

The degree of elevation can provide useful clinical information, but the categories below are approximate and must be interpreted according to the laboratory reference interval and clinical context.

Degree of Elevation	Approximate Magnitude	Possible Clinical Associations
Mild	Less than 5 times the upper reference limit	Steatotic liver disease, chronic viral hepatitis, medication effects, alcohol use, metabolic disorders, or mild muscle injury
Moderate	Approximately 5–15 times the upper reference limit	Acute viral hepatitis, autoimmune hepatitis, drug-related injury, or active chronic liver disease
Marked	More than 15 times the upper reference limit	Ischemic hepatitis, severe toxin-related injury, acute viral hepatitis, or extensive hepatocellular necrosis

Important limitation: The height of the ALT result does not always correlate with the degree of liver dysfunction. A patient with extremely high ALT may recover fully, while a patient with advanced cirrhosis may have normal or only mildly elevated ALT.

10. Aspartate Aminotransferase (AST)

Aspartate aminotransferase (AST), previously known as serum glutamic-oxaloacetic transaminase or SGOT, catalyzes the transfer of an amino group from aspartate to alpha-ketoglutarate.

AST exists in both cytoplasmic and mitochondrial forms. Unlike ALT, AST is distributed widely throughout the body and is therefore less specific for liver injury.

Major Tissue Sources of AST

• Liver
• Cardiac muscle
• Skeletal muscle
• Red blood cells
• Kidneys
• Brain
• Pancreas

Clinical principle: An isolated increase in AST should not automatically be attributed to the liver. Creatine kinase, hemolysis indices, cardiac biomarkers, and the clinical history may be required to identify a non-hepatic source.

Common Causes of Increased AST

• Acute or chronic hepatocellular injury
• Alcohol-associated liver disease
• Ischemic hepatitis
• Drug- or toxin-induced liver injury
• Skeletal muscle trauma or strenuous exercise
• Rhabdomyolysis
• Hemolysis
• Myocardial injury
• Macro-AST, a rare benign cause of persistent isolated AST elevation

AST and Hemolysis

Red blood cells contain AST. In vitro hemolysis during specimen collection, transportation, or processing may therefore cause a falsely increased AST result.

The laboratory should review the hemolysis index when available and interpret AST results cautiously in visibly hemolyzed samples.

Preanalytical caution: A difficult venipuncture, prolonged tourniquet application, vigorous tube shaking, unsuitable transport conditions, or delayed serum separation may contribute to hemolysis and unreliable AST results.

11. ALT versus AST: Key Differences

Feature	ALT	AST
Primary abbreviation	Alanine aminotransferase	Aspartate aminotransferase
Older name	SGPT	SGOT
Relative liver specificity	More liver-specific	Less liver-specific
Cellular location	Mainly cytoplasmic	Cytoplasmic and mitochondrial
Important non-hepatic sources	Muscle and kidney in smaller amounts	Muscle, heart, red blood cells, kidney, and other tissues
Effect of hemolysis	Usually less pronounced	May be significantly increased
Common use	Detection of hepatocellular injury	Assessment of hepatocellular injury with consideration of non-hepatic sources

ALT and AST should usually be interpreted together. The pattern, magnitude, ratio, clinical history, and accompanying test results are more informative than either enzyme alone.

12. AST/ALT Ratio

The AST/ALT ratio, sometimes called the De Ritis ratio, compares the measured AST concentration with the measured ALT concentration.

AST/ALT Ratio Formula

AST/ALT Ratio = AST ÷ ALT

The ratio may support the interpretation of selected liver disorders, but it is not sufficiently specific to establish a diagnosis by itself.

AST/ALT Pattern	Possible Interpretation	Important Limitations
ALT greater than AST	Frequently seen in many forms of acute or chronic hepatocellular injury and metabolic steatotic liver disease	Not specific for one disease
AST/ALT ratio greater than 1	May occur in advanced fibrosis, cirrhosis, alcohol-associated injury, or non-hepatic AST release	Must be correlated with enzyme magnitude and clinical findings
AST/ALT ratio greater than 2	May support alcohol-associated hepatitis when accompanied by a compatible clinical history	Not diagnostic; muscle injury, hemolysis, and advanced liver disease may also increase the ratio
Very high AST and ALT	May suggest ischemic, toxic, or severe acute hepatocellular injury	The ratio is less useful when both enzymes are dramatically elevated

Why AST May Predominate in Alcohol-Associated Liver Injury

Several mechanisms have been proposed to explain the relative predominance of AST in alcohol-associated liver injury:

• Mitochondrial hepatocyte injury may increase mitochondrial AST release.
• Pyridoxal phosphate deficiency may reduce ALT activity more than AST activity.
• Advanced hepatic fibrosis may alter the typical aminotransferase relationship.

Do not diagnose by ratio alone: An AST/ALT ratio above 2 does not prove alcohol-associated liver disease, and a ratio below 2 does not exclude it.

13. Laboratory Measurement of ALT and AST

ALT and AST are commonly measured using kinetic enzymatic methods on automated clinical chemistry analyzers.

The rate of reaction is monitored spectrophotometrically and is proportional to the activity of the enzyme in the patient sample. Laboratories may use methods with or without added pyridoxal-5-phosphate, depending on the reagent system and standardization approach.

General Analytical Principle

The primary aminotransferase reaction is coupled to a secondary reaction involving nicotinamide adenine dinucleotide in its reduced form. The change in absorbance is monitored over time and converted into enzyme activity, usually reported in units per liter.

Important Analytical Considerations

• Method standardization and traceability
• Incubation temperature
• Presence or absence of pyridoxal-5-phosphate
• Reagent lot performance
• Calibration verification
• Internal quality control
• Linearity and analytical measurement range
• Hemolysis, lipemia, and icterus interference

Laboratory practice: Results from different analytical methods may not be directly interchangeable. Patient monitoring should preferably be performed using the same laboratory and method whenever possible.

14. Alkaline Phosphatase (ALP)

Alkaline phosphatase (ALP) is a group of enzymes that hydrolyze phosphate-containing compounds under alkaline conditions. ALP is present in multiple tissues, which makes the interpretation of an increased result dependent on the clinical context.

Main Tissue Sources of ALP

• Liver and bile duct epithelium
• Bone, especially osteoblasts
• Placenta
• Intestine
• Kidney in smaller amounts

Key concept: Increased ALP does not automatically indicate liver disease. Bone growth, pregnancy, fractures, and metabolic bone disease may also increase ALP.

Hepatobiliary Causes of Increased ALP

• Extrahepatic biliary obstruction
• Intrahepatic cholestasis
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Drug-induced cholestasis
• Infiltrative liver disease
• Hepatic metastases
• Cholestatic hepatitis

Non-Hepatic Causes of Increased ALP

• Normal bone growth in children and adolescents
• Pregnancy, particularly during later stages
• Healing fractures
• Paget disease of bone
• Osteomalacia
• Hyperparathyroidism
• Bone malignancy or metastatic bone disease

Physiological Variation

ALP concentrations are normally higher in children and adolescents because of active bone growth. Pregnancy may also increase ALP because of placental enzyme production.

Age-appropriate and pregnancy-specific reference intervals are therefore important for correct interpretation.

Reference interval caution: Applying an adult ALP reference interval to a growing child may lead to an incorrect interpretation of a physiological result as pathological.

15. Determining Whether Increased ALP Is Hepatic or Bone-Related

When ALP is elevated, the next step is to determine the most likely tissue source.

Gamma-Glutamyl Transferase

An increased GGT result together with increased ALP supports a hepatobiliary source because GGT is not significantly produced by bone.

ALP Isoenzymes

ALP isoenzyme testing may help differentiate hepatic, bone, intestinal, and placental fractions when the source remains uncertain.

5′-Nucleotidase

5′-Nucleotidase may also support a hepatobiliary source of increased ALP, although its availability varies among laboratories.

Clinical Correlation

The patient’s age, pregnancy status, symptoms, bone history, medication use, imaging findings, calcium, phosphate, vitamin D, and other test results should be considered.

ALP	GGT	Likely Interpretation
Increased	Increased	Hepatobiliary source is more likely
Increased	Normal	Bone or another non-hepatic source should be considered
Normal	Increased	Enzyme induction, alcohol use, medication effect, or early hepatobiliary disease may be considered
Both normal	Both normal	Significant cholestatic enzyme elevation is not demonstrated

Interpretive shortcut: Increased ALP plus increased GGT usually supports a hepatic or biliary origin. Increased ALP with normal GGT raises greater suspicion for a bone source, but exceptions exist.

16. Laboratory Measurement of ALP

ALP is commonly measured by kinetic colorimetric methods. The enzyme hydrolyzes a phosphate-containing substrate under alkaline conditions, producing a colored compound measured spectrophotometrically.

Analytical Factors Affecting ALP

• Reaction temperature
• Buffer composition and pH
• Substrate concentration
• Magnesium and zinc availability
• Specimen type
• Reagent stability
• Instrument calibration and quality control

ALP measurement may be affected by specimen handling and anticoagulant selection. Chelating anticoagulants can bind essential metal ions and may reduce measured enzyme activity.

Specimen caution: Serum or appropriately validated plasma should be used according to the manufacturer’s instructions. EDTA, citrate, or oxalate plasma may be unsuitable for some ALP methods because these anticoagulants chelate magnesium and zinc.

17. Gamma-Glutamyl Transferase (GGT)

Gamma-glutamyl transferase (GGT), also called gamma-glutamyl transpeptidase, is a membrane-associated enzyme involved in glutathione metabolism and amino acid transport.

GGT is present in the liver, bile ducts, pancreas, kidney, and several other tissues. Serum GGT is particularly useful when evaluating the source of an increased ALP result.

Common Causes of Increased GGT

• Cholestasis and biliary obstruction
• Alcohol use
• Medication-related enzyme induction
• Metabolic steatotic liver disease
• Pancreatic disease
• Chronic liver disease
• Hepatic infiltration

Main clinical use: GGT is highly sensitive to hepatobiliary abnormalities but has limited specificity. It is especially useful for supporting a hepatic origin of elevated ALP.

GGT and Alcohol Use

GGT may increase with chronic alcohol consumption, but it is not specific enough to diagnose alcohol use or alcohol-associated liver disease by itself.

A normal GGT does not exclude harmful alcohol use, and an elevated GGT may be caused by many non-alcohol-related conditions.

Medication Effects

Some medications can induce microsomal enzymes and increase GGT without causing major hepatocellular injury. Medication history is therefore essential when interpreting an isolated GGT elevation.

Interpretive limitation: Because GGT is sensitive but not specific, isolated elevation should not be used as definitive evidence of liver disease, alcohol misuse, or biliary obstruction.

18. Laboratory Measurement of GGT

GGT is typically measured using a kinetic colorimetric method. The enzyme transfers a gamma-glutamyl group from a synthetic substrate to an acceptor molecule, producing a colored reaction product.

The change in absorbance per unit time is proportional to GGT activity in the specimen.

Quality Considerations

• Appropriate reagent storage
• Validated reaction temperature
• Instrument precision
• Linearity at high enzyme activities
• Internal quality control at multiple levels
• Assessment of hemolysis, lipemia, and icterus interference
• Verification of laboratory-specific reference intervals

19. Interpreting a Cholestatic Enzyme Pattern

A cholestatic biochemical pattern is usually characterized by a proportionally greater increase in ALP than in ALT or AST. GGT may also be elevated, and conjugated bilirubin may increase if bile excretion is impaired.

Possible Causes

Extrahepatic Obstruction

Gallstones, biliary strictures, pancreatic masses, or tumors involving the bile ducts may obstruct bile flow.

Intrahepatic Cholestasis

Medications, sepsis, pregnancy-related cholestasis, and inflammatory liver disease may impair bile formation or transport.

Autoimmune Biliary Disease

Primary biliary cholangitis and primary sclerosing cholangitis often produce cholestatic enzyme abnormalities.

Infiltrative Disease

Malignancy, granulomatous disease, and hepatic infiltration may cause disproportionate ALP elevation.

Recommended next steps: A confirmed hepatic cholestatic pattern often requires correlation with bilirubin fractionation, medication history, autoimmune markers, and appropriate imaging of the liver and biliary system.

20. The R Ratio in Liver Injury Classification

The R ratio may be used to classify liver injury as hepatocellular, cholestatic, or mixed, particularly when evaluating suspected drug-induced liver injury.

R Ratio Formula

R = (ALT ÷ ALT Upper Reference Limit) ÷ (ALP ÷ ALP Upper Reference Limit)

R Ratio	Biochemical Pattern
5 or greater	Hepatocellular pattern
2 or less	Cholestatic pattern
Greater than 2 but less than 5	Mixed pattern

Example Calculation

Assume the following:

• ALT result: 300 U/L
• ALT upper reference limit: 40 U/L
• ALP result: 180 U/L
• ALP upper reference limit: 120 U/L

ALT multiple of the upper reference limit: 300 ÷ 40 = 7.5

ALP multiple of the upper reference limit: 180 ÷ 120 = 1.5

R ratio: 7.5 ÷ 1.5 = 5

This result supports a predominantly hepatocellular pattern.

Clinical limitation: The R ratio describes the biochemical pattern; it does not identify the exact diagnosis or determine disease severity by itself.

21. Clinical Interpretation Case Studies

Case 1: Predominantly Hepatocellular Pattern

Test	Result	Interpretation
ALT	850 U/L	Markedly increased
AST	620 U/L	Markedly increased
ALP	145 U/L	Mildly increased
GGT	90 U/L	Increased

The aminotransferase elevation is much greater than the ALP elevation, supporting a hepatocellular pattern. Possible considerations include acute viral hepatitis, drug-induced injury, autoimmune hepatitis, and ischemic liver injury.

Case 2: Cholestatic Pattern

Test	Result	Interpretation
ALT	82 U/L	Mildly increased
AST	70 U/L	Mildly increased
ALP	620 U/L	Markedly increased
GGT	480 U/L	Markedly increased

The marked ALP elevation with increased GGT supports a hepatobiliary cholestatic pattern. Biliary obstruction, cholangitis, medication-related cholestasis, and infiltrative liver disease should be considered.

Case 3: Possible Bone Source of ALP

Test	Result	Interpretation
ALT	Normal	No evidence of aminotransferase elevation
AST	Normal	No evidence of aminotransferase elevation
ALP	Increased	Source must be identified
GGT	Normal	Hepatic source is less likely

Increased ALP with normal GGT and normal aminotransferases raises suspicion for a bone source. Age, fracture history, bone symptoms, vitamin D, calcium, phosphate, and ALP isoenzymes may be helpful.

Case 4: AST Elevation from Muscle Injury

Test	Result	Interpretation
AST	Markedly increased	Could be hepatic or non-hepatic
ALT	Mildly increased	Less pronounced than AST
Creatine kinase	Markedly increased	Supports skeletal muscle injury
ALP and bilirubin	Normal	Cholestasis is not demonstrated

In this pattern, muscle injury is a more likely explanation for the AST elevation than primary liver disease.

22. Common Interpretation Pitfalls

Assuming Every AST Rise Is Hepatic

AST may originate from muscle, red blood cells, cardiac tissue, or other organs.

Diagnosing Alcohol Use from GGT Alone

GGT has poor specificity and may rise in many hepatobiliary and medication-related conditions.

Ignoring Age in ALP Interpretation

Children and adolescents may have physiologically high ALP because of bone growth.

Ignoring Hemolysis

Hemolysis may falsely increase AST and affect other chemistry measurements.

Equating Enzyme Elevation with Liver Failure

ALT and AST indicate injury but do not directly measure synthetic function.

Using Universal Reference Values

Reference intervals vary by method, population, age, sex, and laboratory validation.

23. Part 2 Summary

• ALT is more liver-specific than AST and is a key marker of hepatocellular injury.
• AST is present in liver, muscle, heart, red blood cells, and other tissues.
• The AST/ALT ratio may support clinical interpretation but is not diagnostic by itself.
• ALP elevation may originate from liver, bone, placenta, or other tissues.
• Increased GGT together with increased ALP supports a hepatobiliary source.
• The R ratio helps classify injury as hepatocellular, cholestatic, or mixed.
• Hemolysis, exercise, age, pregnancy, medication use, and analytical methods may influence enzyme results.
• Liver enzymes should always be interpreted as part of a complete biochemical and clinical pattern.

Coming in Part 3

Part 3 will explain total, direct, and indirect bilirubin, bilirubin metabolism, prehepatic, hepatic, and posthepatic jaundice, albumin, total protein, globulin, the albumin-to-globulin ratio, PT/INR, ammonia, and the laboratory assessment of hepatic synthetic function.

Medical and Educational Disclaimer: This content is provided for education and professional development only. It does not replace institutional standard operating procedures, manufacturer instructions, validated laboratory methods, local regulations, clinical judgment, diagnosis, or treatment. Reference intervals and interpretive decisions should be based on the performing laboratory and the individual patient’s clinical condition.

24. Introduction to Bilirubin

Bilirubin is a yellow-orange pigment produced mainly during the breakdown of hemoglobin from aging red blood cells. It is transported to the liver, conjugated by hepatocytes, and excreted into bile.

Measurement of bilirubin is an important component of liver function testing because it provides information about:

• Red blood cell breakdown
• Hepatic uptake of bilirubin
• Bilirubin conjugation
• Biliary secretion
• Bile duct obstruction

Key concept: Bilirubin elevation does not always indicate primary liver disease. Hemolysis, inherited conjugation disorders, impaired hepatocyte function, and biliary obstruction can all cause hyperbilirubinemia.

Main Bilirubin Fractions

Total Bilirubin

Represents the combined concentration of conjugated and unconjugated bilirubin in the blood.

Direct Bilirubin

Primarily reflects conjugated bilirubin, although some laboratory methods may also measure delta bilirubin.

Indirect Bilirubin

Usually calculated by subtracting direct bilirubin from total bilirubin.

Delta Bilirubin

Conjugated bilirubin covalently bound to albumin. It may remain elevated after biliary obstruction begins to resolve.

25. Bilirubin Metabolism

Understanding bilirubin metabolism helps distinguish prehepatic, hepatic, and posthepatic causes of jaundice.

Step 1: Red Blood Cell Breakdown

Senescent red blood cells are removed mainly by macrophages in the spleen, liver, and bone marrow. Hemoglobin is separated into globin and heme.

Heme is converted to biliverdin and then to unconjugated bilirubin.

Step 2: Transport in Blood

Unconjugated bilirubin is poorly soluble in water. It travels through the bloodstream tightly bound to albumin.

Important: Because unconjugated bilirubin is albumin-bound and water-insoluble, it is not normally filtered into urine.

Step 3: Hepatic Uptake

Unconjugated bilirubin is taken up by hepatocytes and transported to the smooth endoplasmic reticulum.

Step 4: Conjugation

The enzyme uridine diphosphate-glucuronosyltransferase, commonly abbreviated as UGT1A1, conjugates bilirubin with glucuronic acid.

The resulting conjugated bilirubin is water-soluble and can be excreted into bile.

Step 5: Biliary Excretion

Conjugated bilirubin is actively transported from hepatocytes into bile canaliculi and then passes through the biliary system into the intestine.

Step 6: Intestinal Metabolism

Intestinal bacteria convert conjugated bilirubin into urobilinogen. Most is oxidized to stercobilin, which gives stool its brown color.

A small amount of urobilinogen is reabsorbed into the portal circulation. Some is re-excreted by the liver, while a small portion reaches the kidneys and is converted to urobilin, contributing to the yellow color of urine.

Suggested Figure for This Section Flow diagram showing red blood cell destruction, heme breakdown, unconjugated bilirubin transport with albumin, hepatic conjugation, biliary excretion, intestinal urobilinogen, stercobilin, and urinary urobilin.

26. Unconjugated Hyperbilirubinemia

Unconjugated hyperbilirubinemia occurs when indirect bilirubin represents the predominant elevated fraction.

This pattern usually results from increased bilirubin production, reduced hepatic uptake, or impaired bilirubin conjugation.

Common Causes

Hemolysis

Increased red blood cell destruction produces more bilirubin than the liver can efficiently conjugate.

Resorption of Hematoma

Breakdown of a large collection of extravascular blood may increase bilirubin production.

Ineffective Erythropoiesis

Destruction of erythroid precursors in the bone marrow may increase unconjugated bilirubin.

Gilbert Syndrome

A common inherited condition associated with reduced UGT1A1 activity and mild intermittent unconjugated hyperbilirubinemia.

Crigler–Najjar Syndrome

A rare inherited disorder involving severe deficiency or absence of bilirubin-conjugating activity.

Neonatal Jaundice

Reduced hepatic conjugation capacity may cause increased unconjugated bilirubin in newborns.

Laboratory Pattern Suggesting Hemolysis

Laboratory Test	Typical Finding in Hemolysis
Indirect bilirubin	Increased
Reticulocyte count	Increased
Lactate dehydrogenase	Increased
Haptoglobin	Reduced, especially in intravascular hemolysis
Hemoglobin	May be reduced
Urine bilirubin	Usually absent

Interpretation principle: Isolated unconjugated hyperbilirubinemia with normal ALT, AST, ALP, and blood counts may suggest an inherited conjugation disorder such as Gilbert syndrome. Evidence of anemia, reticulocytosis, high LDH, and low haptoglobin favors hemolysis.

27. Conjugated Hyperbilirubinemia

Conjugated hyperbilirubinemia occurs when direct bilirubin represents a substantial proportion of the elevated total bilirubin.

It usually reflects impaired excretion of conjugated bilirubin from hepatocytes or obstruction of bile flow.

Common Causes

• Extrahepatic biliary obstruction
• Intrahepatic cholestasis
• Acute or chronic hepatitis
• Drug-induced liver injury
• Sepsis-associated cholestasis
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Dubin–Johnson syndrome
• Rotor syndrome

Urine Bilirubin

Conjugated bilirubin is water-soluble and can be filtered by the kidneys. Therefore, urine bilirubin may become positive in conjugated hyperbilirubinemia.

Clinical clue: Dark urine in a jaundiced patient often suggests conjugated hyperbilirubinemia because conjugated bilirubin is excreted in urine.

Delta Bilirubin

During prolonged conjugated hyperbilirubinemia, some bilirubin becomes covalently attached to albumin, forming delta bilirubin.

Because albumin has a relatively long half-life, direct bilirubin may remain elevated after biliary obstruction or hepatic injury begins to improve.

28. Prehepatic, Hepatic, and Posthepatic Jaundice

Jaundice can be classified according to the main site of bilirubin disturbance.

Type of Jaundice	Main Mechanism	Typical Laboratory Pattern
Prehepatic	Excess bilirubin production before hepatic processing	Predominantly indirect bilirubin, urine bilirubin absent, hemolysis markers may be abnormal
Hepatic	Impaired uptake, conjugation, hepatocyte processing, or excretion	Mixed direct and indirect bilirubin elevation; ALT and AST may be increased
Posthepatic	Obstruction of bile flow after bilirubin conjugation	Predominantly direct bilirubin, increased ALP and GGT, positive urine bilirubin

Prehepatic Jaundice

Prehepatic jaundice most commonly results from excessive bilirubin production due to hemolysis or ineffective erythropoiesis.

The liver may be structurally normal, but bilirubin production exceeds its conjugating capacity.

Hepatic Jaundice

Hepatic jaundice occurs when hepatocytes cannot adequately take up, conjugate, or excrete bilirubin.

Viral hepatitis, drug-induced injury, cirrhosis, autoimmune hepatitis, and inherited transport disorders may produce this pattern.

Posthepatic Jaundice

Posthepatic jaundice results from obstruction of bile flow. Causes include gallstones, pancreatic tumors, biliary strictures, and cholangiocarcinoma.

ALP and GGT are typically increased disproportionately compared with aminotransferases.

29. Laboratory Measurement of Bilirubin

Bilirubin is commonly measured using diazo-based colorimetric methods or other validated chemistry analyzer techniques.

Total bilirubin methods measure bilirubin after the addition of an accelerator that allows both conjugated and unconjugated bilirubin to react.

Direct bilirubin methods measure bilirubin that reacts without the same accelerating conditions.

Indirect Bilirubin Calculation

Formula

Indirect Bilirubin = Total Bilirubin − Direct Bilirubin

Important Preanalytical Factors

• Exposure of the specimen to light
• Hemolysis
• Lipemia
• Delayed sample processing
• Improper storage temperature
• Medication or chemical interference

Light sensitivity: Bilirubin is photosensitive. Prolonged exposure of the specimen to strong light may cause bilirubin degradation and falsely low results.

Specimen Handling

Serum or validated plasma may be used according to the analytical method. The specimen should be protected from excessive light and analyzed promptly or stored according to laboratory procedures.

30. Albumin

Albumin is the most abundant plasma protein and is synthesized primarily by the liver.

It contributes significantly to plasma oncotic pressure and serves as a transport protein for many substances.

Major Functions of Albumin

• Maintenance of plasma oncotic pressure
• Transport of bilirubin
• Transport of fatty acids
• Binding of calcium
• Transport of hormones
• Binding and transport of many medications
• Antioxidant and buffering functions

Key interpretation: Serum albumin is more useful as a marker of chronic hepatic synthetic impairment than acute hepatocellular injury because albumin has a relatively long circulating half-life.

Causes of Low Albumin

Reduced Hepatic Synthesis

Advanced chronic liver disease may reduce albumin production.

Inflammation

Albumin is a negative acute-phase reactant and may decrease during systemic inflammation.

Renal Protein Loss

Nephrotic syndrome may cause substantial urinary albumin loss.

Gastrointestinal Loss

Protein-losing enteropathy may reduce serum albumin.

Malnutrition

Severe or prolonged inadequate protein intake may contribute to low albumin.

Dilution

Fluid overload, pregnancy, or excessive intravenous fluid administration may reduce albumin concentration.

Causes of Increased Albumin

Clinically significant hyperalbuminemia is uncommon and most often reflects dehydration or hemoconcentration.

Interpretive limitation: Low albumin is not specific for liver disease. Renal disease, inflammation, malnutrition, gastrointestinal loss, burns, and dilution must also be considered.

31. Laboratory Measurement of Albumin

Albumin is commonly measured using dye-binding methods such as bromocresol green or bromocresol purple.

Bromocresol Green Method

At an acidic pH, albumin binds to bromocresol green and produces a colored complex. The color intensity is proportional to the albumin concentration.

Bromocresol Purple Method

Bromocresol purple may offer greater specificity for albumin in some settings, although method-dependent differences can occur.

Potential Analytical Limitations

• Method-specific interference from globulins
• Differences between dye-binding techniques
• Hemolysis, lipemia, or icterus interference
• Reduced accuracy at very low albumin concentrations
• Differences between laboratories and analyzer systems

Laboratory practice: Serial albumin measurements should preferably be compared using the same analytical method and laboratory.

32. Total Protein

Total protein represents the combined concentration of albumin and globulins in serum or plasma.

Basic Relationship

Total Protein = Albumin + Globulins

Major Protein Components

• Albumin
• Alpha-1 globulins
• Alpha-2 globulins
• Beta globulins
• Gamma globulins

Causes of Increased Total Protein

• Dehydration
• Chronic inflammation
• Chronic infection
• Polyclonal gammopathy
• Monoclonal gammopathy
• Plasma cell disorders

Causes of Reduced Total Protein

• Reduced protein synthesis
• Malnutrition
• Nephrotic syndrome
• Protein-losing enteropathy
• Severe burns
• Hemodilution
• Advanced liver disease

Laboratory Measurement

Total protein is commonly measured using the biuret method. Peptide bonds react with copper ions in an alkaline environment to form a colored complex measured spectrophotometrically.

33. Globulin and Albumin-to-Globulin Ratio

Serum globulin is often calculated rather than measured directly.

Calculated Globulin

Globulin = Total Protein − Albumin

Albumin-to-Globulin Ratio

A/G Ratio = Albumin ÷ Globulin

Causes of Reduced A/G Ratio

• Reduced albumin synthesis
• Chronic liver disease
• Chronic inflammation
• Autoimmune disease
• Polyclonal hypergammaglobulinemia
• Monoclonal gammopathy
• Renal albumin loss

Causes of Increased A/G Ratio

• Reduced immunoglobulin concentration
• Some immunodeficiency states
• Laboratory or calculation-related variation

Important: An abnormal globulin concentration or A/G ratio may require serum protein electrophoresis, immunofixation, immunoglobulin measurement, or other investigations depending on the clinical context.

34. Prothrombin Time and INR

The liver synthesizes most coagulation factors. Therefore, prothrombin time (PT) and international normalized ratio (INR) may provide useful information about hepatic synthetic function.

PT evaluates the extrinsic and common coagulation pathways and is influenced by several clotting factors, including factors I, II, V, VII, and X.

Why PT May Change Quickly

Factor VII has a relatively short half-life. Reduced hepatic synthesis may therefore produce PT prolongation earlier than changes in albumin.

Clinical principle: PT/INR may be more responsive than albumin to acute deterioration in hepatic synthetic capacity.

Causes of Prolonged PT/INR

• Severe acute liver injury
• Advanced chronic liver disease
• Vitamin K deficiency
• Warfarin therapy
• Disseminated intravascular coagulation
• Coagulation factor deficiencies
• Massive transfusion
• Laboratory specimen problems

Vitamin K Deficiency versus Liver Failure

Cholestasis may impair absorption of fat-soluble vitamin K, causing prolonged PT/INR.

Improvement after appropriate vitamin K administration may support deficiency rather than severe loss of hepatic synthetic capacity.

Interpretive limitation: INR was developed primarily to standardize monitoring of vitamin K antagonist therapy. It should be interpreted cautiously in patients with liver disease and does not provide a complete assessment of bleeding or thrombosis risk.

35. Ammonia

Ammonia is produced during amino acid metabolism and by intestinal bacterial activity.

The liver converts ammonia into urea through the urea cycle, allowing it to be excreted by the kidneys.

Causes of Increased Ammonia

• Advanced liver failure
• Portosystemic shunting
• Urea-cycle disorders
• Severe gastrointestinal bleeding
• Some medications
• Renal dysfunction
• Increased protein catabolism
• Preanalytical specimen errors

Ammonia and Hepatic Encephalopathy

Increased ammonia may contribute to hepatic encephalopathy, but the relationship between ammonia concentration and clinical severity is not always consistent.

Clinical limitation: Hepatic encephalopathy is a clinical diagnosis. A normal ammonia result does not completely exclude it, and an elevated result does not by itself establish the diagnosis.

Preanalytical Requirements

Ammonia testing is highly sensitive to collection and handling errors. Incorrect handling may cause falsely elevated results.

• Avoid prolonged tourniquet application
• Avoid repeated fist clenching
• Use the validated specimen type
• Transport and process the specimen rapidly
• Follow laboratory temperature requirements
• Separate plasma or serum promptly when required
• Avoid contamination and hemolysis

Laboratory principle: Ammonia results should not be released without assessing specimen quality, collection time, transport conditions, and processing delay.

36. Assessing Hepatic Synthetic Function

Hepatic synthetic function is primarily assessed using albumin and coagulation-related tests, particularly PT/INR.

Marker	Main Information	Major Limitations
Albumin	Longer-term hepatic protein synthesis	Affected by inflammation, nutrition, renal loss, gastrointestinal loss, and dilution
PT/INR	Production of several coagulation factors	Affected by vitamin K deficiency, anticoagulants, DIC, and factor deficiencies
Total protein	Combined albumin and globulin concentration	Influenced by hydration and immunoglobulin changes
Cholesterol	May decrease in advanced hepatic failure	Influenced by nutrition, metabolism, and medication
Glucose	Severe liver failure may impair glucose regulation	Influenced by diabetes, fasting, stress, and treatment

Acute versus Chronic Changes

In acute liver injury, PT/INR may change more rapidly than albumin. Albumin may initially remain normal because of its long half-life.

In chronic liver disease, persistent low albumin may reflect prolonged reduction in protein synthesis, although non-hepatic causes must still be considered.

Key Interpretation Rule

• ALT and AST indicate injury.
• ALP and GGT indicate cholestasis.
• Bilirubin reflects processing and excretion.
• Albumin and PT/INR help assess synthetic function.

37. Clinical Interpretation Case Studies

Case 1: Hemolytic Pattern

Test	Result
Total bilirubin	Increased
Indirect bilirubin	Predominantly increased
ALT and AST	Normal or minimally changed
Reticulocyte count	Increased
LDH	Increased
Haptoglobin	Reduced

This pattern supports increased bilirubin production due to hemolysis rather than primary cholestatic liver disease.

Case 2: Gilbert Syndrome Pattern

Test	Result
Total bilirubin	Mildly increased
Indirect bilirubin	Predominantly increased
ALT, AST, ALP, and GGT	Normal
Hemoglobin and reticulocytes	Normal

Mild intermittent unconjugated hyperbilirubinemia with otherwise normal laboratory findings may suggest Gilbert syndrome after excluding hemolysis and other causes.

Case 3: Obstructive Jaundice

Test	Result
Total bilirubin	Markedly increased
Direct bilirubin	Predominantly increased
ALP	Markedly increased
GGT	Markedly increased
ALT and AST	Mildly or moderately increased
Urine bilirubin	Positive

This pattern is consistent with cholestasis or biliary obstruction and usually requires imaging correlation.

Case 4: Reduced Synthetic Function

Test	Result
Albumin	Reduced
PT/INR	Prolonged
Total bilirubin	Increased
Platelet count	May be reduced
ALT and AST	May be mildly increased or near normal

This pattern may occur in advanced chronic liver disease. Mild enzyme elevations do not exclude severe functional impairment.

38. Common Interpretation Pitfalls

Assuming All Jaundice Is Hepatic

Hemolysis and inherited bilirubin disorders can cause jaundice with normal liver enzymes.

Ignoring Bilirubin Fractionation

Direct and indirect bilirubin provide essential information about the mechanism of hyperbilirubinemia.

Using Albumin as an Acute Marker

Albumin changes slowly and may remain normal early in acute liver injury.

Assuming Low Albumin Means Cirrhosis

Renal loss, inflammation, malnutrition, and dilution are common alternative causes.

Interpreting INR Without Context

Warfarin, vitamin K deficiency, DIC, and factor deficiencies may prolong INR.

Poor Ammonia Handling

Delayed processing and collection errors can cause falsely elevated ammonia results.

Exposing Bilirubin to Light

Prolonged light exposure may degrade bilirubin and produce falsely low results.

Ignoring Delta Bilirubin

Direct bilirubin may remain elevated during recovery because albumin-bound delta bilirubin clears slowly.

39. Part 3 Summary

• Bilirubin is produced mainly from heme breakdown and is processed by the liver before biliary excretion.
• Unconjugated bilirubin is water-insoluble and transported while bound to albumin.
• Conjugated bilirubin is water-soluble and may appear in urine.
• Predominantly indirect hyperbilirubinemia suggests increased production or impaired conjugation.
• Predominantly direct hyperbilirubinemia suggests impaired biliary excretion or cholestasis.
• Albumin provides information about longer-term protein synthesis but is affected by many non-hepatic conditions.
• Total protein includes albumin and globulins, while the A/G ratio may help identify abnormal protein distribution.
• PT/INR may change rapidly during severe hepatic synthetic dysfunction.
• Ammonia testing requires strict preanalytical control and should not be interpreted independently of the clinical picture.
• Liver-related tests should always be interpreted together rather than as isolated numerical results.

Coming in Part 4

Part 4 will cover specimen collection, preanalytical errors, analytical methods, quality control, reference intervals, laboratory interference, structured interpretation of hepatocellular and cholestatic patterns, and detailed clinical case studies.

Medical and Educational Disclaimer: This content is provided for education and professional development only. It does not replace institutional standard operating procedures, manufacturer instructions, validated laboratory methods, local regulations, clinical judgment, diagnosis, or treatment. Reference intervals and interpretive decisions should be based on the performing laboratory and the individual patient’s clinical condition.

40. Specimen Collection for Liver Function Tests

Accurate interpretation of liver function tests begins with proper patient preparation, specimen collection, transportation, processing, and storage. Preanalytical errors may produce misleading results even when the analytical method is functioning correctly.

Serum is commonly used for liver-related chemistry tests, although many laboratories also validate lithium-heparin plasma. The acceptable specimen type must always follow the analyzer and reagent manufacturer’s instructions and the laboratory’s validated procedure.

Key laboratory principle: A technically accurate result from an unsuitable or poorly handled specimen may still be clinically unreliable.

Commonly Accepted Specimens

Test	Common Specimen	Important Notes
ALT, AST, ALP, GGT	Serum or validated heparinized plasma	Avoid unsuitable chelating anticoagulants for ALP because they may bind essential metal ions.
Total and direct bilirubin	Serum or validated plasma	Protect the sample from excessive light exposure.
Albumin and total protein	Serum or validated plasma	Plasma total protein may be slightly higher because fibrinogen is present.
PT/INR	Sodium citrate plasma	Correct tube filling and an appropriate blood-to-anticoagulant ratio are essential.
Ammonia	Method-specific plasma specimen	Requires rapid transport and processing according to the laboratory protocol.

Patient Preparation

Fasting is not universally required for all liver tests. However, the patient’s dietary state may influence some related chemistry results and may contribute to lipemia.

Laboratories and clinical services should follow local policies regarding fasting, medication timing, alcohol intake, physical activity, and repeat testing.

• Record current medications and herbal supplements.
• Document recent strenuous exercise when relevant.
• Consider recent alcohol intake.
• Identify pregnancy status when interpreting ALP.
• Use age-appropriate reference intervals.
• Review recent transfusion, surgery, or trauma history.

41. Major Preanalytical Errors

Preanalytical errors are among the most common causes of inaccurate laboratory results. Several specimen-related problems may significantly affect liver function tests.

Hemolysis

Red blood cell rupture may release AST and other intracellular components, producing falsely elevated results.

Lipemia

Turbid specimens may interfere with photometric assays and can affect result accuracy depending on the method.

Icterus

Very high bilirubin concentrations may interfere with selected chemistry reactions and optical measurements.

Light Exposure

Bilirubin is photosensitive and may degrade when exposed to strong light for prolonged periods.

Delayed Separation

Prolonged contact between serum or plasma and cells may alter analyte concentrations and specimen quality.

Wrong Anticoagulant

Some anticoagulants may interfere with enzyme activity or produce unsuitable samples for specific tests.

Incorrect Tube Filling

Underfilled citrate tubes may produce inaccurate PT and INR results.

Prolonged Tourniquet Use

Hemoconcentration may alter protein-related measurements and other chemistry results.

Hemolysis and AST

AST is present in red blood cells. Therefore, hemolysis may cause an apparent AST increase without true hepatocellular injury.

A hemolyzed specimen may also affect LDH, potassium, and other analytes. The laboratory should assess the hemolysis index and apply validated rejection or comment criteria.

Important: A high AST result from a visibly hemolyzed specimen should not be interpreted as liver injury until specimen integrity has been assessed.

Light Exposure and Bilirubin

Bilirubin may decrease when the specimen is exposed to direct sunlight or strong artificial light. Samples should be protected according to the laboratory procedure, especially when transport or testing is delayed.

Ammonia Handling

Ammonia is particularly sensitive to collection and handling errors. Cellular metabolism may continue after collection and falsely increase the measured concentration.

• Use the validated collection tube.
• Avoid unnecessary tourniquet time.
• Avoid repeated fist clenching.
• Transport immediately.
• Process within the laboratory-defined time limit.
• Follow the validated temperature requirements.

42. Specimen Rejection Criteria

Specimen rejection criteria should be defined in the laboratory’s standard operating procedures and supported by manufacturer instructions and method validation.

Specimen Problem	Potential Effect	Possible Laboratory Action
Unlabeled or misidentified specimen	Patient identification error	Reject according to patient identification policy
Gross hemolysis	False AST increase and other analytical interference	Reject or report with validated interference comment
Severe lipemia	Photometric interference	Use validated correction, alternate method, ultracentrifugation, or recollection
Excessive light exposure	Falsely low bilirubin	Request recollection when clinically significant
Wrong specimen type	Method interference or invalid result	Reject and request a correct specimen
Clotted citrate specimen	Invalid PT/INR	Reject
Underfilled citrate tube	Excess anticoagulant and falsely prolonged clotting time	Reject according to the laboratory policy
Delayed ammonia processing	Falsely increased result	Reject or recollect based on validation criteria

Quality requirement: Rejection decisions should be consistent, documented, traceable, and communicated clearly to the requesting clinical team.

43. Analytical Methods Used in Liver Function Testing

Most liver-related biomarkers are measured on automated clinical chemistry analyzers using kinetic, colorimetric, spectrophotometric, or immunochemical methods.

Analyte	Common Analytical Principle	General Measurement Approach
ALT	Kinetic enzymatic method	Rate of NADH consumption is monitored spectrophotometrically
AST	Kinetic enzymatic method	Coupled enzymatic reaction with absorbance monitoring
ALP	Kinetic colorimetric method	Hydrolysis of a phosphate-containing substrate under alkaline conditions
GGT	Kinetic colorimetric method	Transfer of a gamma-glutamyl group to an acceptor substrate
Total bilirubin	Diazo or alternative colorimetric method	Measurement after reaction of total bilirubin fractions
Direct bilirubin	Direct diazo reaction or validated alternative	Measures rapidly reacting bilirubin fractions
Albumin	Dye-binding method	Bromocresol green or bromocresol purple binding
Total protein	Biuret method	Peptide bonds react with copper ions in alkaline solution
PT/INR	Clot-based coagulation method	Time to clot formation after thromboplastin and calcium addition
Ammonia	Enzymatic method	Method-dependent reaction linked to spectrophotometric measurement

Method Standardization

Results may vary between instruments and reagent systems because of differences in reaction conditions, calibration, temperature, pyridoxal-5-phosphate supplementation, substrate composition, and traceability.

Laboratories should verify method performance before routine use and assess comparability when changing analyzers, reagents, or methodologies.

Interpretive caution: A result obtained using one analytical system may not be directly interchangeable with a result from another system.

44. Method Verification and Validation

Before implementing a liver function test method, the laboratory must demonstrate that the analytical system performs acceptably under local operating conditions.

Common Performance Characteristics

• Precision
• Trueness or bias
• Analytical measurement range
• Linearity
• Detection capability when relevant
• Carryover
• Interference
• Reference interval verification
• Method comparison
• Clinical reportable range

Precision

Precision studies assess the reproducibility of repeated measurements. Both within-run and between-run variation may be evaluated using quality control materials or appropriate patient samples.

Bias

Bias describes the systematic difference between the measured result and an accepted target or comparative method.

Linearity

Linearity confirms that results remain proportional to analyte concentration across the claimed analytical range.

Carryover

Carryover occurs when a high-concentration sample affects the result of a subsequent sample. It should be assessed during method implementation when relevant to the analyzer design.

61. Major Liver Diseases and Typical Laboratory Patterns

Liver function tests can identify a biochemical pattern, but they rarely establish the exact diagnosis independently. The final interpretation requires correlation with clinical history, medications, imaging, serology, immunological tests, metabolic investigations, and sometimes histological examination.

Important: The patterns below are educational summaries. Individual patients may present with atypical, overlapping, or nearly normal laboratory results.

Condition	Typical Laboratory Pattern	Useful Additional Investigations
Acute viral hepatitis	Marked ALT and AST elevation, usually with ALT predominance; bilirubin may increase.	Viral serology, molecular tests, PT/INR, bilirubin, renal function, and clinical assessment.
Chronic viral hepatitis	Mild, moderate, fluctuating, or occasionally normal aminotransferase activities.	Viral load, antigen and antibody testing, fibrosis assessment, ultrasound, and specialist evaluation.
Metabolic dysfunction-associated steatotic liver disease	ALT may exceed AST in earlier disease; GGT may increase; enzymes may remain normal despite steatosis or fibrosis.	Metabolic profile, FIB-4, elastography, imaging, glucose, HbA1c, lipids, and fibrosis risk assessment.
Alcohol-associated liver disease	AST may exceed ALT; GGT and bilirubin may increase; albumin and PT/INR may become abnormal in advanced disease.	Clinical history, CBC, MCV, bilirubin, PT/INR, renal function, imaging, and fibrosis assessment.
Autoimmune hepatitis	Predominantly hepatocellular pattern with increased ALT and AST; immunoglobulin G may be elevated.	ANA, ASMA, anti-LKM antibodies, IgG, exclusion of viral disease, and liver biopsy when indicated.
Primary biliary cholangitis	Persistent cholestatic pattern, particularly increased ALP and GGT.	Antimitochondrial antibodies, immunoglobulins, imaging, and specialist assessment.
Primary sclerosing cholangitis	Cholestatic pattern with increased ALP and GGT; bilirubin may rise with advanced disease or obstruction.	Cholangiographic imaging, inflammatory bowel disease assessment, and specialist evaluation.
Drug-induced liver injury	Hepatocellular, cholestatic, or mixed pattern depending on the responsible agent.	Complete medication and supplement history, R ratio, exclusion of alternative causes, and serial monitoring.
Ischemic hepatitis	Very marked aminotransferase elevation, often with substantial LDH elevation.	Hemodynamic history, cardiac assessment, renal function, lactate, PT/INR, and serial enzyme measurements.
Extrahepatic biliary obstruction	Increased ALP, GGT, and direct bilirubin; aminotransferases may rise, especially early in acute obstruction.	Ultrasound, cross-sectional imaging, cholangiographic evaluation, and surgical or gastroenterology consultation.
Hemochromatosis	Variable aminotransferase elevation; abnormalities may be mild before advanced liver injury develops.	Ferritin, transferrin saturation, genetic testing when indicated, imaging, and fibrosis assessment.
Wilson disease	Variable hepatocellular abnormalities; acute presentations may include jaundice, hemolysis, and coagulopathy.	Ceruloplasmin, urinary copper, ophthalmological assessment, hepatic copper, and genetic evaluation when appropriate.
Alpha-1 antitrypsin deficiency	Variable aminotransferase abnormalities and possible chronic liver disease.	Alpha-1 antitrypsin concentration, phenotype or genotype, imaging, and fibrosis assessment.
Advanced cirrhosis	Low albumin, prolonged PT/INR, increased bilirubin, reduced platelets, and mild or even normal aminotransferases.	Imaging, elastography, portal hypertension assessment, renal function, sodium, and hepatocellular carcinoma surveillance.

62. Viral Hepatitis

Viral hepatitis may produce acute or chronic hepatocellular injury. Laboratory findings depend on the causative virus, stage of infection, immune response, comorbidities, and severity of liver involvement.

Typical Acute Pattern

• Marked ALT and AST elevation
• ALT often higher than AST
• Variable total and direct bilirubin elevation
• Normal or mildly increased ALP
• Possible PT/INR prolongation in severe injury

Typical Chronic Pattern

• Persistent or fluctuating mild aminotransferase elevation
• Normal enzyme activities in some patients
• Possible progressive fibrosis despite modest abnormalities
• Reduced albumin or prolonged PT/INR in advanced disease
• Thrombocytopenia when portal hypertension develops

Clinical principle: Normal ALT does not reliably exclude chronic viral infection, fibrosis, or cirrhosis. Disease-specific serological and molecular tests are required.

63. Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with hepatic steatosis and cardiometabolic risk factors such as obesity, insulin resistance, type 2 diabetes, hypertension, and dyslipidemia.

Possible Laboratory Findings

• Mild or moderate ALT elevation
• AST lower than ALT during earlier disease
• Increased GGT in some patients
• Normal or mildly increased ALP
• Increased glucose, HbA1c, or triglycerides
• Increasing AST/ALT ratio with advanced fibrosis
• Reduced platelet count in advanced portal hypertension

Important limitation: Normal aminotransferase results do not exclude steatohepatitis or advanced fibrosis. Fibrosis risk should not be assessed from ALT alone.

Suggested Assessment

1. Evaluate metabolic risk factors.
2. Exclude significant competing causes of liver disease.
3. Calculate an appropriate first-line fibrosis score.
4. Use elastography or another second-line test when indicated.
5. Refer higher-risk or uncertain cases for specialist assessment.

64. Alcohol-Associated Liver Disease

Alcohol-associated liver disease may range from steatosis to steatohepatitis, fibrosis, cirrhosis, and acute decompensation.

Possible Laboratory Findings

• AST higher than ALT
• AST/ALT ratio sometimes greater than 2
• Increased GGT
• Increased bilirubin in clinically significant hepatitis
• Prolonged PT/INR in severe disease
• Reduced albumin in chronic advanced disease
• Macrocytosis or increased MCV
• Thrombocytopenia in portal hypertension

Interpretive caution: Neither GGT nor the AST/ALT ratio proves alcohol exposure. Results require respectful and confidential correlation with the clinical history.

65. Drug-Induced Liver Injury

Drug-induced liver injury, or DILI, may be caused by prescription medicines, non-prescription products, herbal preparations, bodybuilding products, or dietary supplements.

DILI may produce hepatocellular, cholestatic, mixed, autoimmune-like, or other biochemical patterns.

Laboratory Assessment

• ALT and AST
• ALP and GGT
• Total and direct bilirubin
• Albumin
• PT/INR
• Renal function
• CBC and eosinophil count when relevant
• R ratio calculation

Important History

• Exact product name
• Dose and frequency
• Treatment start date
• Date of symptom onset
• Date of laboratory abnormality
• Date treatment was stopped
• Previous exposure to the same product
• Use of supplements or herbal preparations

Key principle: DILI is usually a diagnosis of exclusion. Viral, autoimmune, biliary, ischemic, metabolic, and muscle-related causes may need to be evaluated.

Safety warning: Suspected severe DILI, jaundice, coagulopathy, confusion, hypoglycemia, or clinical deterioration requires urgent medical assessment.

66. Autoimmune and Cholestatic Liver Diseases

Autoimmune Hepatitis

Usually produces a hepatocellular pattern. IgG may be increased, and autoantibodies may support the diagnosis.

Primary Biliary Cholangitis

Usually produces persistent ALP and GGT elevation. Antimitochondrial antibodies are an important diagnostic marker.

Primary Sclerosing Cholangitis

Typically produces a cholestatic biochemical pattern and requires appropriate biliary imaging.

Overlap Syndromes

Some patients demonstrate combined hepatocellular, cholestatic, serological, and histological features.

Autoantibody positivity alone does not establish a diagnosis. Results must be interpreted with immunoglobulin concentrations, imaging, histology, medication history, and exclusion of competing diseases.

67. Cirrhosis and Hepatic Decompensation

Cirrhosis represents advanced architectural distortion and fibrosis of the liver. Patients may remain compensated for a period before developing decompensating events.

Possible Laboratory Findings

• Reduced albumin
• Prolonged PT/INR
• Increased bilirubin
• Reduced platelet count
• Hyponatremia in advanced disease
• Renal dysfunction during decompensation
• Variable ALT, AST, ALP, and GGT results

Clinical Features of Decompensation

• Ascites
• Variceal bleeding
• Hepatic encephalopathy
• Progressive jaundice
• Spontaneous bacterial peritonitis
• Hepatorenal dysfunction

Critical point: Advanced cirrhosis may be present with normal or only mildly elevated ALT and AST. Functional markers, platelet count, imaging, elastography, and clinical findings are essential.

68. Assessment of Liver Fibrosis

Fibrosis assessment estimates the amount of scar tissue in the liver and helps identify patients at increased risk of cirrhosis, portal hypertension, decompensation, and hepatocellular carcinoma.

Main Assessment Categories

Simple Blood-Based Scores

Examples include FIB-4 and APRI. They use routine laboratory and demographic data.

Specialized Blood Tests

Examples include proprietary fibrosis panels and direct markers of extracellular matrix turnover.

Elastography

Measures liver stiffness using ultrasound-based or magnetic resonance techniques.

Liver Biopsy

Provides histological information but is invasive and has sampling and interpretation limitations.

Modern approach: Sequential non-invasive testing is commonly used. A simple blood-based score may be followed by elastography or a specialized test in patients who are not clearly low risk.

69. Fibrosis-4 Index (FIB-4)

The FIB-4 index is a non-invasive fibrosis risk score calculated from age, AST, ALT, and platelet count.

FIB-4 Formula

FIB-4 = (Age × AST) ÷ [Platelet Count × √ALT]

Required Units

• Age in years
• AST in U/L
• ALT in U/L
• Platelet count in 10⁹/L

Example Calculation

• Age: 50 years
• AST: 60 U/L
• ALT: 50 U/L
• Platelets: 180 × 10⁹/L

FIB-4 = (50 × 60) ÷ [180 × √50]

FIB-4 ≈ 2.36

This result should be interpreted using the validated pathway appropriate to the patient’s age, disease type, clinical setting, and local guideline.

Do not use one universal cutoff for every patient: FIB-4 performance and thresholds vary with age, disease prevalence, clinical setting, and underlying liver condition. Acute illness and thrombocytopenia from non-hepatic causes may produce misleading results.

Important Limitations

• Reduced accuracy in younger adults
• More false-positive results in older adults
• Unreliable interpretation during acute liver injury
• Influence of non-hepatic thrombocytopenia
• Influence of muscle-related AST elevation
• Not a replacement for clinical assessment

70. AST-to-Platelet Ratio Index (APRI)

The AST-to-platelet ratio index, abbreviated as APRI, combines AST elevation with platelet count to estimate the probability of significant fibrosis or cirrhosis in selected chronic liver diseases.

APRI Formula

APRI = [(AST ÷ AST Upper Reference Limit) ÷ Platelet Count] × 100

Example Calculation

• AST: 80 U/L
• AST upper reference limit: 40 U/L
• Platelets: 150 × 10⁹/L

APRI = [(80 ÷ 40) ÷ 150] × 100 = 1.33

Interpretive limitation: APRI should be applied only within an appropriate validated clinical pathway. AST changes and non-hepatic platelet abnormalities can influence the result.

71. Limitations of Non-Invasive Fibrosis Tests

Factor	Possible Effect
Acute hepatitis	Increased AST and ALT may falsely increase blood-based fibrosis scores and liver stiffness.
Cholestasis	May increase liver stiffness independently of fibrosis.
Hepatic congestion	May increase liver stiffness.
Recent food intake	May affect some elastography measurements.
Older age	May increase FIB-4 and reduce specificity.
Young age	May reduce the sensitivity of FIB-4.
Thrombocytopenia unrelated to liver disease	May falsely increase FIB-4 or APRI.
Muscle injury	AST elevation may falsely increase fibrosis scores.

Best practice: Non-invasive tests should be interpreted as part of a sequential clinical pathway rather than as isolated diagnostic results.

72. Monitoring Patients with Liver Disease

Monitoring frequency and test selection depend on the diagnosis, treatment, baseline severity, medication exposure, comorbidities, and risk of decompensation.

Common Monitoring Parameters

• ALT and AST
• ALP and GGT
• Total and direct bilirubin
• Albumin
• PT/INR
• CBC and platelet count
• Creatinine and estimated glomerular filtration rate
• Sodium and glucose
• Disease-specific viral, autoimmune, or metabolic markers
• Imaging or elastography when appropriate

Why Trends Matter

Serial results help determine whether the biochemical abnormality is improving, worsening, fluctuating, or stable. Trends are generally more informative when testing is performed using the same laboratory and analytical method.

Important: Falling ALT and AST do not always indicate recovery. During massive loss of viable hepatocytes, enzyme activities may fall while bilirubin, PT/INR, hypoglycemia, encephalopathy, or organ failure worsens.

73. Laboratory Red Flags Requiring Urgent Assessment

Urgent assessment may be necessary when abnormal liver tests are accompanied by evidence of functional deterioration, systemic illness, or rapidly progressive disease.

Coagulopathy

New or worsening PT/INR prolongation may indicate impaired hepatic synthesis or another serious coagulation disorder.

Altered Mental Status

Confusion or reduced consciousness with liver injury may indicate hepatic encephalopathy or another medical emergency.

Hypoglycemia

Low glucose may occur in severe hepatic failure and requires urgent treatment.

Rapid Bilirubin Increase

Progressive jaundice may indicate worsening hepatic dysfunction or significant obstruction.

Renal Dysfunction

Rising creatinine in advanced liver disease may indicate severe systemic or hepatorenal complications.

Sepsis or Hemodynamic Instability

Hypotension, fever, or shock with abnormal liver tests requires rapid clinical evaluation.

Emergency warning: Jaundice accompanied by confusion, bleeding, severe abdominal pain, persistent vomiting, fever, hypotension, hypoglycemia, or rapidly worsening laboratory results requires immediate medical assessment.

74. Liver Function Tests in Children

Pediatric liver test interpretation requires age-specific reference intervals and consideration of growth, neonatal physiology, congenital disorders, and age-dependent disease patterns.

Important Pediatric Considerations

• ALP is commonly higher during periods of active bone growth.
• Neonates may develop physiological unconjugated hyperbilirubinemia.
• Conjugated hyperbilirubinemia in an infant requires prompt evaluation.
• Prematurity can influence bilirubin metabolism.
• Inherited metabolic disorders may present with liver dysfunction.
• Medication doses and toxic exposures differ from adults.
• Pediatric fibrosis scores require pediatric validation.

Pediatric safety point: Adult reference intervals and adult fibrosis algorithms should not be applied automatically to children.

75. Liver Function Tests During Pregnancy

Pregnancy produces physiological changes that may alter selected laboratory results. Abnormal findings must be interpreted using pregnancy-appropriate clinical and laboratory information.

Possible Physiological Changes

• ALP may rise because of placental production.
• Albumin may decrease because of plasma-volume expansion.
• Reference intervals may vary by trimester and laboratory.

Important Pregnancy-Related Disorders

• Hyperemesis gravidarum-associated liver abnormalities
• Intrahepatic cholestasis of pregnancy
• Preeclampsia
• HELLP syndrome
• Acute fatty liver of pregnancy
• Biliary obstruction or gallstone disease

Urgent assessment: Pregnancy with jaundice, hypertension, thrombocytopenia, hemolysis, abdominal pain, hypoglycemia, coagulopathy, or rapidly worsening liver tests requires urgent multidisciplinary evaluation.

76. Liver Test Interpretation in Older Adults

Interpretation in older adults should consider polypharmacy, frailty, nutritional status, chronic disease, malignancy, biliary disease, cardiac congestion, and age-related changes in fibrosis scores.

Important Considerations

• Multiple medications increase the possibility of DILI.
• FIB-4 may produce more false-positive results with advancing age.
• Low albumin may reflect inflammation, frailty, or malnutrition.
• Heart failure may cause congestive hepatopathy.
• Malignancy may cause obstruction or hepatic infiltration.
• Mild enzyme abnormalities may still require structured evaluation.

77. Differential Diagnosis by Laboratory Pattern

Laboratory Pattern	Possible Causes	Useful Follow-Up
ALT and AST predominant	Viral hepatitis, DILI, autoimmune hepatitis, ischemia, MASLD, alcohol-associated disease, muscle injury.	History, serology, medication review, CK, autoimmune tests, imaging, PT/INR.
ALP and GGT predominant	Biliary obstruction, cholestatic drug reaction, PBC, PSC, infiltration, sepsis-associated cholestasis.	Bilirubin fractionation, ultrasound, autoimmune markers, medication review, additional imaging.
Increased ALP with normal GGT	Bone growth, fracture, vitamin D deficiency, metabolic bone disease, bone malignancy, placental ALP.	Age, pregnancy status, calcium, phosphate, vitamin D, imaging, ALP isoenzymes.
Isolated AST elevation	Muscle injury, hemolysis, exercise, cardiac injury, macro-AST, liver disease.	CK, LDH, hemolysis index, clinical history, repeat testing, macro-AST investigation.
Indirect bilirubin predominant	Hemolysis, ineffective erythropoiesis, Gilbert syndrome, Crigler–Najjar syndrome, hematoma resorption.	CBC, reticulocytes, LDH, haptoglobin, blood film, clinical history.
Direct bilirubin predominant	Cholestasis, obstruction, hepatitis, DILI, inherited bilirubin transport disorders.	ALP, GGT, imaging, medication review, serology, autoimmune tests.
Low albumin	Chronic liver dysfunction, inflammation, renal loss, gastrointestinal loss, malnutrition, burns, dilution.	Urine protein, CRP, nutritional evaluation, renal function, total protein, clinical assessment.
Prolonged PT/INR	Liver dysfunction, vitamin K deficiency, anticoagulant therapy, DIC, inherited or acquired factor deficiency.	Medication review, coagulation profile, fibrinogen, D-dimer, mixing studies, clinical assessment.

78. Final Integrated Case Studies

Case 1: Acute Hepatocellular Injury

Test	Result
ALT	1,850 U/L
AST	1,420 U/L
ALP	145 U/L
Total bilirubin	68 µmol/L
INR	1.7

The marked aminotransferase elevation indicates a hepatocellular pattern. The prolonged INR raises concern about impaired hepatic synthetic function and increases the urgency of clinical assessment.

Possible causes include acute viral hepatitis, toxin-related injury, drug-induced liver injury, ischemic hepatitis, and autoimmune hepatitis.

Case 2: Extrahepatic Cholestasis

Test	Result
ALT	95 U/L
AST	80 U/L
ALP	720 U/L
GGT	610 U/L
Direct bilirubin	Markedly increased

The disproportionate ALP and GGT elevations with conjugated hyperbilirubinemia indicate a cholestatic pattern. Imaging is needed to evaluate possible obstruction.

Case 3: Possible Gilbert Syndrome

Test	Result
Total bilirubin	Mildly increased
Indirect bilirubin	Predominantly increased
ALT, AST, ALP, and GGT	Normal
Hemoglobin and reticulocytes	Normal
LDH and haptoglobin	No evidence of hemolysis

Mild isolated unconjugated hyperbilirubinemia without hemolysis or other liver abnormalities may support Gilbert syndrome after appropriate clinical evaluation.

Case 4: Advanced Chronic Liver Disease

Test	Result
ALT	48 U/L
AST	65 U/L
Albumin	Reduced
INR	Prolonged
Bilirubin	Increased
Platelets	Reduced

Mild enzyme elevation does not exclude advanced disease. The albumin, INR, bilirubin, and platelet abnormalities suggest impaired function and possible portal hypertension.

Case 5: Muscle Injury

Test	Result
AST	420 U/L
ALT	95 U/L
CK	9,500 U/L
ALP, GGT, and bilirubin	Normal

The very high CK and AST-predominant pattern support skeletal muscle injury rather than primary liver disease.

79. Frequently Asked Questions

1. What are liver function tests?

Liver function tests are a group of laboratory tests used to assess hepatocellular injury, cholestasis, bilirubin metabolism, protein synthesis, and coagulation-related hepatic function.

2. Which tests are usually included in an LFT panel?

A typical panel may include ALT, AST, ALP, GGT, total bilirubin, direct bilirubin, albumin, and total protein. PT/INR may be ordered separately.

3. Are ALT and AST true liver function tests?

ALT and AST primarily indicate cellular injury. They do not directly measure how effectively the liver performs its synthetic and metabolic functions.

4. Which enzyme is more specific for liver injury?

ALT is generally more liver-specific than AST. AST is also present in skeletal muscle, cardiac muscle, red blood cells, kidneys, and other tissues.

5. Can liver disease occur with normal ALT and AST?

Yes. Significant steatosis, fibrosis, chronic viral disease, and cirrhosis may occur with normal or mildly elevated aminotransferases.

6. What does a high ALP result mean?

Increased ALP may originate from the liver, bile ducts, bone, placenta, or other tissues. GGT, clinical history, age, pregnancy status, imaging, or ALP isoenzymes may help identify the source.

7. What does high ALP with high GGT suggest?

This combination supports a hepatobiliary source and may occur in cholestasis or biliary obstruction.

8. What does high ALP with normal GGT suggest?

A bone or another non-hepatic source becomes more likely, although exceptions are possible.

9. What is the AST/ALT ratio?

It is calculated by dividing AST by ALT. It may support pattern recognition but cannot establish a specific diagnosis independently.

10. Does an AST/ALT ratio above 2 prove alcohol-related disease?

No. It may support alcohol-associated injury in a compatible clinical context, but other liver and non-liver conditions can produce the same pattern.

11. What is the difference between direct and indirect bilirubin?

Indirect bilirubin is predominantly unconjugated and water-insoluble. Direct bilirubin mainly reflects conjugated, water-soluble bilirubin.

12. Can bilirubin appear in urine?

Conjugated bilirubin is water-soluble and may appear in urine. Unconjugated bilirubin is albumin-bound and is not normally filtered by the kidneys.

13. Does low albumin always mean liver disease?

No. Low albumin may result from inflammation, kidney loss, gastrointestinal protein loss, malnutrition, burns, fluid overload, or chronic liver dysfunction.

14. Why is PT/INR important in liver disease?

The liver synthesizes multiple coagulation factors. PT/INR may become prolonged when hepatic synthetic capacity is significantly impaired, although several non-hepatic causes must be excluded.

15. What is the R ratio?

The R ratio compares ALT elevation with ALP elevation relative to their upper reference limits and helps classify injury as hepatocellular, cholestatic, or mixed.

16. What is FIB-4?

FIB-4 is a non-invasive fibrosis risk score calculated from age, AST, ALT, and platelet count. It is used within validated clinical pathways, often as an initial risk-stratification test.

17. Can FIB-4 diagnose cirrhosis by itself?

No. It estimates risk and may indicate whether additional assessment is needed. It should be interpreted with clinical information and other non-invasive or diagnostic tests.

18. Does hemolysis affect liver test results?

Yes. Hemolysis may falsely increase AST and interfere with several chemistry assays. The hemolysis index and specimen quality should be reviewed.

19. Why must bilirubin specimens be protected from light?

Bilirubin is photosensitive. Excessive light exposure can degrade it and cause falsely low results.

20. When are abnormal LFTs an emergency?

Urgent assessment is necessary when abnormal results are accompanied by confusion, bleeding, coagulopathy, hypoglycemia, severe jaundice, hypotension, fever, severe pain, renal dysfunction, or rapid clinical deterioration.

80. Complete Guide Summary

Essential Interpretation Framework

• ALT and AST: primarily indicate hepatocellular injury.
• ALP and GGT: help identify cholestasis and hepatobiliary involvement.
• Total and direct bilirubin: assess bilirubin production, conjugation, transport, and excretion.
• Albumin and PT/INR: provide information about hepatic synthetic function but are not liver-specific.
• Platelet count: may support assessment of fibrosis and portal hypertension.
• FIB-4 and APRI: estimate fibrosis risk within validated clinical pathways.
• Clinical context: remains essential for every interpretation.

Final Interpretation Steps

1. Confirm patient identification and specimen suitability.
2. Use method-specific and age-appropriate reference intervals.
3. Determine whether the pattern is hepatocellular, cholestatic, or mixed.
4. Fractionate bilirubin when hyperbilirubinemia is present.
5. Assess albumin, PT/INR, glucose, renal function, and clinical status.
6. Consider muscle, bone, hemolytic, pregnancy-related, and inherited causes.
7. Review medications, supplements, alcohol exposure, and metabolic risk.
8. Compare current and previous results.
9. Use non-invasive fibrosis tests when clinically appropriate.
10. Escalate urgent abnormalities according to institutional policy.

Final message: Liver function tests should never be interpreted as isolated numbers. Reliable interpretation combines analytical quality, biochemical pattern, disease probability, serial trends, imaging, and the patient’s complete clinical condition.

81. Scientific References and Further Reading

1. American Association for the Study of Liver Diseases. Practice Guidelines and Guidance Documents.
2. American Association for the Study of Liver Diseases. Non-Invasive Liver Disease Assessment Practice Guidelines.
3. European Association for the Study of the Liver. Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis.
4. American College of Gastroenterology. Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
5. National Institute of Diabetes and Digestive and Kidney Diseases. Diagnosis and Assessment of Cirrhosis and Chronic Liver Disease.
6. International Federation of Clinical Chemistry and Laboratory Medicine. Reference Procedures and Standardization of Enzyme Measurements.
7. Clinical and Laboratory Standards Institute. Method Verification, Reference Intervals, Interference Testing, and Quality Control Guidelines.
8. McPherson RA, Pincus MR, editors. Henry’s Clinical Diagnosis and Management by Laboratory Methods.
9. Rifai N, Horvath AR, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine.
10. Burtis CA, Bruns DE. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics.

Reference note: Guidelines, nomenclature, diagnostic thresholds, and clinical pathways may change. Readers should consult the latest official edition and their local institutional requirements.

About the Author

OA

Prepared by Dr. Omar Adwan

Medical Laboratory Technologist and founder of MedLab Academy, providing educational content in clinical chemistry, hematology, microbiology, blood banking, molecular diagnostics, quality control, and laboratory medicine.

LinkedIn  •  Email

Medical and Educational Disclaimer: This article is provided for education and professional development only. It does not replace institutional standard operating procedures, manufacturer instructions, validated laboratory methods, accreditation requirements, local regulations, clinical examination, medical diagnosis, or treatment. Laboratory reference intervals, specimen requirements, analytical interference limits, critical values, fibrosis thresholds, and clinical pathways vary between institutions and patient populations. Healthcare professionals must use the performing laboratory’s validated procedures and evaluate every patient individually.

Edit This Article